Carcinomas
Research from University of Wisconsin in the Area of Carcinomas Published
Published in Drug Week, November 25th, 2011
2011 NOV 25 -- New research, "Pilot trial of interleukin-2 and zoledronic acid to augment 'd T cells as treatment for patients with refractory renal cell carcinoma," is the subject of a report. "Prior to the advent of VEGF-targeted therapies, renal cell carcinoma (RCC) was among the few solid tumors shown to respond to cytokine-based therapies such as interleukin-2 (IL-2) and interferon alpha. Previous work has shown that aminobisphosphonates, including zoledronic acid (ZA), are capable of activating human V'9 Vd2 T cells in vitro, and these cells can be further expanded with IL-2," scientists in Madison, Wisconsin report.
"Moreover, these V'9 Vd2 T cells...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2011-11-25)
More Articles from Drug Week
- Psychiatry
Data from University of Geneva Advance Knowledge in Psychiatry - Ampicillins
Data on Ampicillins Discussed by H. Akhter and Colleagues - Apoptosis
Data on Apoptosis Reported by Researchers at Sungkyunkwan University - Cancer Therapy
Data on Cancer Therapy Published by Researchers at Southern Medical University - Drug Development
Data on Drug Development Discussed by A.D. Ruikar and Colleagues - Nanoparticles
Data on Nanoparticles Discussed by S. Vrignaud and Colleagues - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
